Sickle Cell Disorders
9
2
2
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
22.2%
2 terminated out of 9 trials
60.0%
-26.5% vs benchmark
11%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD
GenoMed4ALL: Improving SCD Classification and Prognosis by AI
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
Effects of HQK-1001 in Patients With Sickle Cell Disease
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
Safety Study of MP4CO in Adult Sickle Cell Patients
A Study of HQK-1001 in Patients With Sickle Cell Disease